Tigray Health Research Institute, Mekelle, Ethiopia.
Department of Microbiology and Immunology, Division for Biomedical Sciences, College of Health Science, Mekelle University, Mekelle, Ethiopia.
AIDS Res Ther. 2022 Dec 1;19(1):57. doi: 10.1186/s12981-022-00479-8.
Although Ethiopia is endemic to viral hepatitis and HIV, data that could guide population-specific interventions are limited. In this study, we determined the seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) and assessed their associations with HIV-1 viral load suppression among HIV-1 infected patients on antiretroviral therapy (ART) at Mekelle hospital in northern Ethiopia.
Between February and April 2020, blood samples were collected from 439 participants. Samples were screened for HBsAg and anti-HCV on the immunochromatographic test and confirmed using the Enzyme-Linked Immuno-sorbent assay (Beijing Wantai Co. China). HIV-1 viral load was quantified using reverse transcription-polymerase chain reaction (RT-PCR) on the Abbott platform. Binary and multivariable logistic regression was performed to identify potential predictors.
Overall, 10% (44/439) and 3.6% (16/439) of the participants were coinfected with HBV and HCV, respectively. In a multivariate analysis, being illiterate (AOR = 6.57; 95% CI 1.04-41.6), and having a history of sexually transmitted infections (AOR = 4.44; 95% CI 1.31-15.0) and multiple sexual partners (AOR = 29.9; 95% CI 7.82-114.8) were associated with HBV infection. On the other hand, participants with a history of chronic non-communicable diseases (AOR = 10.6, 95% CI 1.61-70.1), and those reporting a history of sexually transmitted infections (AOR = 5.21, 95% CI 1.39-19.5) were more likely to be infected with HCV. In further analysis, HCV infection status was significantly associated with decreased viral load suppression rate (AOR = 7.14; 95% CI 2.18-23.3) whereas no significant association was observed with the HBV infection.
The HBV coinfection rate in our study is high and, as per WHO's standard, corresponds to a hyperendemic level. The HCV coinfection rate is also substantially high and urges attention given its influence on the viral load suppression of HIV patients on ART at our study site. Our findings suggest the need to adopt universal screening and vaccination of people with HIV against HBV and screening for HCV at our study site and in Ethiopia at large, which contributes to Ethiopia's progress towards the 2030 global target of reducing the HBV infection.
尽管埃塞俄比亚是病毒性肝炎和艾滋病毒的流行地区,但能够指导特定人群干预措施的数据有限。在这项研究中,我们确定了在埃塞俄比亚北部的 Mekelle 医院接受抗逆转录病毒疗法 (ART) 的艾滋病毒 1 型 (HIV-1) 感染者中乙型肝炎病毒 (HBV) 和丙型肝炎病毒 (HCV) 的血清流行率,并评估了它们与 HIV-1 病毒载量抑制的关系。
2020 年 2 月至 4 月期间,从 439 名参与者中采集了血液样本。使用免疫层析试验对 HBsAg 和抗-HCV 进行了筛查,并使用酶联免疫吸附试验(北京万泰公司)进行了确认。使用 Abbott 平台的逆转录-聚合酶链反应 (RT-PCR) 定量 HIV-1 病毒载量。采用二项和多变量逻辑回归来确定潜在的预测因素。
总体而言,10%(44/439)和 3.6%(16/439)的参与者分别同时感染了 HBV 和 HCV。在多变量分析中,不识字(AOR=6.57;95%CI 1.04-41.6)、有性传播感染史(AOR=4.44;95%CI 1.31-15.0)和多个性伴侣(AOR=29.9;95%CI 7.82-114.8)与 HBV 感染相关。另一方面,有慢性非传染性疾病史的参与者(AOR=10.6,95%CI 1.61-70.1)和有性传播感染史的参与者(AOR=5.21,95%CI 1.39-19.5)更有可能感染 HCV。进一步分析表明,HCV 感染状况与病毒载量抑制率降低显著相关(AOR=7.14;95%CI 2.18-23.3),而与 HBV 感染无显著相关性。
我们研究中的 HBV 合并感染率很高,按照世界卫生组织的标准,相当于高度流行水平。HCV 的合并感染率也相当高,这引起了我们的关注,因为它会影响到我们研究地点和整个埃塞俄比亚接受 ART 的 HIV 患者的病毒载量抑制。我们的研究结果表明,需要在我们的研究地点和埃塞俄比亚普遍筛查和为 HIV 感染者接种乙型肝炎疫苗,并筛查 HCV,这有助于埃塞俄比亚实现到 2030 年降低乙型肝炎感染的全球目标。